Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial
Alastair J.S. Webb,Jacqueline Birks,Karolina A. Feakins,Amy Lawson,Jesse Dawson,Alexander M.K. Rothman,David J. Werring,Osian Llwyd,Catriona Stewart,James Thomas
DOI: https://doi.org/10.1161/circresaha.124.324327
IF: 23.213
2024-06-06
Circulation Research
Abstract:Circulation Research, Ahead of Print. BACKGROUND:Vascular cognitive impairment due to cerebral small vessel disease is associated with cerebral pulsatility, white matter hypoperfusion, and reduced cerebrovascular reactivity (CVR), and is potentially improved by endothelium-targeted drugs such as cilostazol. Whether sildenafil, a phosphodiesterase-5 inhibitor, improves cerebrovascular dysfunction is unknown.METHODS:OxHARP trial (Oxford Haemodynamic Adaptation to Reduce Pulsatility) was a double-blind, randomized, placebo-controlled, 3-way crossover trial after nonembolic cerebrovascular events with mild-moderate white matter hyperintensities (WMH), the most prevalent manifestation of cerebral small vessel disease. The primary outcome assessed the superiority of 3 weeks of sildenafil 50 mg thrice daily versus placebo (mixed-effect linear models) on middle cerebral artery pulsatility, derived from peak systolic and end-diastolic velocities (transcranial ultrasound), with noninferiority to cilostazol 100 mg twice daily. Secondary end points included the following: cerebrovascular reactivity during inhalation of air, 4% and 6% CO2on transcranial ultrasound (transcranial ultrasound-CVR); blood oxygen-level dependent–magnetic resonance imaging within WMH (CVR-WMH) and normal-appearing white matter (CVR-normal-appearing white matter); cerebral perfusion by arterial spin labeling (magnetic resonance imaging pseudocontinuous arterial spin labeling); and resistance by cerebrovascular conductance. Adverse effects were compared by Cochran Q.RESULTS:In 65/75 (87%) patients (median, 70 years;79% male) with valid primary outcome data, cerebral pulsatility was unchanged on sildenafil versus placebo (0.02, −0.01 to 0.05;P=0.18), or versus cilostazol (−0.01, −0.04 to 0.02;P=0.36), despite increased blood flow (∆ peak systolic velocity, 6.3 cm/s, 3.5–9.07;P<0.001; ∆ end-diastolic velocity, 1.98, 0.66–3.29;P=0.004). Secondary outcomes improved on sildenafil versus placebo for CVR-transcranial ultrasound (0.83 cm/s per mm Hg, 0.23–1.42;P=0.007), CVR-WMH (0.07, 0–0.14;P=0.043), CVR-normal-appearing white matter (0.06, 0.00–0.12;P=0.048), perfusion (WMH: 1.82 mL/100 g per minutes, 0.5–3.15;P=0.008; and normal-appearing white matter, 2.12, 0.66–3.6;P=0.006) and cerebrovascular resistance (sildenafil-placebo: 0.08, 0.05–0.10;P=4.9×10−8; cilostazol-placebo, 0.06, 0.03–0.09;P=5.1×10−5). Both drugs increased headaches (P=1.1×10−4), while cilostazol increased moderate-severe diarrhea (P=0.013).CONCLUSIONS:Sildenafil did not reduce pulsatility but increased cerebrovascular reactivity and perfusion. Sildenafil merits further study to determine whether it prevents the clinical sequelae of small vessel disease.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT03855332.
cardiac & cardiovascular systems,peripheral vascular disease,hematology